S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
NASDAQ:AMLX

Amylyx Pharmaceuticals - AMLX Stock Forecast, Price & News

$25.50
+0.68 (+2.74%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.00
▼
$26.18
50-Day Range
$8.55
▼
$26.99
52-Week Range
$6.51
▼
$33.41
Volume
660,381 shs
Average Volume
795,111 shs
Market Capitalization
$1.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
54.9% Upside
$39.50 Price Target
Short Interest
Bearish
12.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.55) to ($0.41) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

1024th out of 1,098 stocks

Pharmaceutical Preparations Industry

495th out of 536 stocks

See Top Rated MarketRank™ Stocks Here
AMLX stock logo

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $25.50 on Wednesday. The firm has a fifty day moving average price of $19.64 and a two-hundred day moving average price of $17.95. Amylyx Pharmaceuticals has a one year low of $6.51 and a one year high of $33.41.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.18). Sell-side analysts forecast that Amylyx Pharmaceuticals will post -3.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Citigroup raised their price target on Amylyx Pharmaceuticals from $33.00 to $37.00 and gave the stock a "buy" rating in a report on Wednesday, July 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $39.50.

Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Stock News Headlines

July 29, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
July 21, 2022 | americanbankingnews.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap Down to $20.49
July 18, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
July 5, 2022 | nasdaq.com
Amylyx Pharma: FDA Plans To Reconvene Advisory Committee To Review AMX0035 NDA On Sept. 7
July 5, 2022 | msn.com
U.S. FDA to reconvene experts' meeting for Amylyx ALS drug
July 5, 2022 | seekingalpha.com
Amylyx stock rises 8% as FDA panel sets September meeting to discuss ALS drug
July 5, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
July 5, 2022 | finance.yahoo.com
UPDATE 2-U.S. FDA to reconvene experts' meeting for Amylyx ALS drug
July 5, 2022 | finance.yahoo.com
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
July 5, 2022 | finance.yahoo.com
Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again
June 28, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
June 17, 2022 | seekingalpha.com
Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
June 15, 2022 | reuters.com
Amylyx's ALS drug would not be cost effective if priced around $170,000- ICER
June 14, 2022 | seekingalpha.com
Amylyx Pharma stock adds ~25% a day after Canadian conditional approval for ALS therapy
June 14, 2022 | finance.yahoo.com
Here's How Citi Views Amylyx Pharma
June 14, 2022 | finance.yahoo.com
Amylyx's ALS drug would be more cost effective if priced around $170,000- ICER
June 13, 2022 | markets.businessinsider.com
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September
June 13, 2022 | seekingalpha.com
Amylyx wins Canadian approval for ALS therapy under conditions
June 13, 2022 | msn.com
Amylyx gets first approval for ALS drug from Canada
June 3, 2022 | benzinga.com
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today
June 3, 2022 | markets.businessinsider.com
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate
June 3, 2022 | investorplace.com
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
June 3, 2022 | seekingalpha.com
Amylyx stock rises 16% as FDA extends review period of ALS drug which failed panel backing
June 3, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
June 3, 2022 | finance.yahoo.com
Amylyx says FDA decision date for ALS therapy is now in September; shares jump
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Company Calendar

Last Earnings
5/12/2022
Today
8/10/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMLX
CUSIP
N/A
CIK
1658551
Web
amylyx.com
Phone
617-683-0917
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.50
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+54.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.58
Quick Ratio
9.58

Sales & Book Value

Annual Sales
$280,000.00
Price / Sales
5,330.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.68) per share
Price / Book
-9.51

Miscellaneous

Outstanding Shares
58,533,000
Free Float
51,099,000
Market Cap
$1.49 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Joshua Cohen (Age 30)
    Co-Founder, Co-CEO & Director
    Comp: $726.53k
  • Mr. Justin Klee (Age 31)
    Co-Founder, Co-CEO & Director
    Comp: $726.53k
  • Mr. James M. Frates (Age 55)
    Chief Financial Officer
    Comp: $1.2M
  • Ms. Margaret M. Olinger M.B.A (Age 57)
    Global Head of Commercial & Chief Commercial Officer
    Comp: $567k
  • Ms. Gina M. Mazzariello (Age 51)
    Chief Legal Officer & Gen. Counsel
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 63)
    Global Head of HR & CHRO
  • Mr. Tom Holmes
    Global Head of Supply Chain
  • Dr. Patrick D. Yeramian M.D. (Age 63)
    MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer
  • Mr. Chris Aiello
    Head of Canada & GM

Key Competitors

View All Competitors













AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price forecast for 2022?

5 analysts have issued 1-year price objectives for Amylyx Pharmaceuticals' shares. Their AMLX share price forecasts range from $35.00 to $50.00. On average, they predict the company's stock price to reach $39.50 in the next year. This suggests a possible upside of 54.9% from the stock's current price.
View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts.

How has Amylyx Pharmaceuticals' stock price performed in 2022?

Amylyx Pharmaceuticals' stock was trading at $20.61 at the beginning of 2022. Since then, AMLX shares have increased by 23.7% and is now trading at $25.50.
View the best growth stocks for 2022 here.

When is Amylyx Pharmaceuticals' next earnings date?

Amylyx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our AMLX earnings forecast.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings data on Thursday, May, 12th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by $0.18.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

What is Amylyx Pharmaceuticals' stock symbol?

Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amylyx Pharmaceuticals' stock price today?

One share of AMLX stock can currently be purchased for approximately $25.50.

How much money does Amylyx Pharmaceuticals make?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.49 billion and generates $280,000.00 in revenue each year.

How many employees does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals employs 34 workers across the globe.

How can I contact Amylyx Pharmaceuticals?

The official website for the company is amylyx.com. The company can be reached via phone at 617-683-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.